When is crossover desirable in cancer drug trials and when is it problematic?

TY - JOUR

T1 - When is crossover desirable in cancer drug trials and when is it problematic?

AU - Haslam, A.

AU - Prasad, V.

PY - 2018/5/1

Y1 - 2018/5/1

UR - http://www.scopus.com/inward/record.url?scp=85047609411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047609411&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy116

DO - 10.1093/annonc/mdy116

M3 - Editorial

AN - SCOPUS:85047609411

SN - 0923-7534

VL - 29

SP - 1080

JO - Annals of Oncology

JF - Annals of Oncology

IS - 5

ER -